Article Text

Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey
Free
  1. Corrado Campochiaro1,
  2. Giorgia Trignani1,
  3. Alessandro Tomelleri1,
  4. Stefano Cascinu2,
  5. Lorenzo Dagna1
  6. COVID-19 Vaccine Study Group
    1. 1 Università Vita-Salute San Raffaele, School of Medicine; Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
    2. 2 Università Vita-Salute San Raffaele, School of Medicine; Unit of Oncology, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
    1. Correspondence to Dr Corrado Campochiaro, Università Vita-Salute San Raffaele, School of Medicine; Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, 20132 Milano, Lombardia, Italy; campochiaro.corrado{at}hsr.it

    Statistics from Altmetric.com

    Similarly to the general population, advanced age, comorbidities and chronic glucocorticoid treatment (≥10 mg/day prednisone-equivalent) have been identified as negative prognostic factors for COVID-19 also in rheumatological patients.1 2Unfortunately, until today, the only effective recommended strategy to reduce the rate of SARS-CoV-2 infection in rheumatological patients has been the application of preventive life-style measures, such as social distancing and the use of personal protective equipment.3 Hopefully, the recently approved COVID-19 vaccines will revolutionise our approach to the pandemic.4 Although the details of the COVID-19 vaccination plan are yet to be defined in most EU countries, it is expected that rheumatological patients, together with other groups of patients suffering from chronic diseases, will be considered a priority group.5

    To investigate the likelihood of COVID-19 vaccine acceptance, we performed a survey in a cohort of consecutive rheumatological patients followed up at our tertiary referral centre in Milan, Italy. A cohort of patients with neoplastic diseases followed up at the Oncologic Department of the same Institution was included as comparator. All patients provided their informed consent for the use of their anonymous data. The details of the self-administered questionnaire are available as an online supplemental material.

    Between 23 November and 11 December 2020, a total of 202 rheumatological patients and 68 oncological patients answered to the questionnaire. Table 1 summarises their main demographic and clinical features. Overall, 222 (82%) patients declared to be willing to receive COVID-19 vaccine, with no differences between the two groups: 88 rheumatological (44%) and 26 oncological (38%) patients clearly expressed their willingness (p=0.48), while 74 rheumatological (37%) and 34 oncological (50%) patients gave an affirmative answer provided a recommendation by the treating physician (p=0.06). The proportions of patients openly opposed or sceptical were also similar (17% vs 9%, p=0.12). Interestingly, rheumatological patients had a higher mean score at the likelihood visual analogue scale (7.37±2.68 vs 6.63±2.62, p=0.029). Reasons for declining COVID-19 vaccination among rheumatological patients were fear of adverse reactions (n=14) and of rheumatic disease worsening (n=3), safety concerns related to the rapidity of vaccine production (n=6), doubt on its usefulness (n=1), and a generalised vaccine hesitancy (n=1). When completing the questionnaire, 25 rheumatological and 2 oncological patients had been already diagnosed with COVID-19; nonetheless, a prior COVID-19 diagnosis did not influence the vaccination acceptance rate (80% in both subgroups). In rheumatological patients, among clinical and demographic factors, only a higher level of education (college and postgraduate degree 92% vs primary and middle school 67%, p=0.01) was associated with a greater willingness to get vaccinated. Of interest, concomitant therapies did not correlate with the desire of getting vaccinated. Finally, in both groups, patients who joined 2020 influenza vaccine campaign were keener to get COVID-19 vaccination (90% vs 36%, p<0.01).

    Table 1

    Demographic and clinical features of rheumatological and oncological patients

    Although the small number of patients included, a few conclusions can be drawn from this survey. The most reassuring data are the majority of our rheumatological patients consider positively the opportunity of undergoing COVID-19 vaccination and have even a higher likelihood score when compared with oncological patients. Moreover, even though intrinsic factors such as the level of education still play a major determinant role, rheumatologists’ recommendations seem to have a fundamental positive influence. This is particularly important for patients concerned about vaccine-induced rheumatic disease worsening who should be reassured that a potential disease flare could be adequately treated after vaccination. To date, recommendations for COVID-19 vaccination in rheumatological patients are still lacking; nonetheless, international societies advise in favour of extensive vaccinations in these groups of patients.6 The third millennium ‘V-day’ has just happened but several months will be needed for a satisfactory coverage. Physicians and patients are in urgent need of coordinated national and international local awareness campaigns to defeat COVID-19 vaccine scepticism and hopefully put an end to this pandemic.

    References

    Supplementary materials

    • Supplementary Data

      This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Footnotes

    • Handling editor Josef S Smolen

    • Collaborators COVID-19 Vaccine Study Group: Giacomo De Luca, Giulio Cavalli, Luca Moroni, Silvia Sartorelli, Emanuel Della Torre, Elena Baldissera, Nicola Boffini, Giulia Di Colo, Adriana Cariddi, Vanesa Gregorc, Giampaolo Bianchini, Michele Reni, Monica Ronzoni.

    • Contributors CC, GT, AT and the COVID-19 Vaccine Study Group collected the data. AT and CC analysed the data. CC, AT, SC and LD wrote the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.